JPMorgan Has 3 Top Pick Large Cap Pharmas To Buy For The Rest Of 2017

One segment in the markets that has been dogged with issues for almost two years is the big pharmaceuticals, as numerous factors have kept the lid on share prices and, in some cases, kept the headlines right in investors’ faces. The biggest issue is the seemingly constant and somewhat shrill rhetoric from attention-seeking politicians over drug prices. While that may play well with constituents, it can be difficult for companies trying to deliver for shareholders.